Company / EPS (Diluted)
BeOne Medicines Ltd. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.65
FY2025
5-year range
-$1.50 / -$0.65
FY2021-FY2025
Trend
+56.4%
vs FY2024
Sector context
#75 of 204
Health Care
What the data says
At $-0.65, BeOne Medicines Ltd.'s eps (diluted) ranks #75 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1.50 in FY2022 to $-0.10 in FY2017.
Based on SEC 10-K filings.
-0.65 in FY2025.
Improved from $-1.21 to $-0.65 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#75 of 204 in Health CareTop 37% of 204This company -$0.65 Sector average -$0.98
▼
+33.6% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 56.4% year-over-year.
- Ranks #75 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.65 | +56.4% |
| FY2024 | -$1.49 | -23.1% |
| FY2023 | -$1.21 | +19.3% |
| FY2022 | -$1.50 | -24.0% |
| FY2021 | -$1.21 | -30.1% |
| FY2020 | -$0.93 | -447.1% |
| FY2019 | -$0.17 | +43.3% |
| FY2018 | -$0.30 | -200.0% |
| FY2017 | -$0.10 | +44.4% |
| FY2016 | -$0.18 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026